BR112012018954A2 - derivados de hetaril-[1,8]naftiridina - Google Patents
derivados de hetaril-[1,8]naftiridinaInfo
- Publication number
- BR112012018954A2 BR112012018954A2 BR112012018954A BR112012018954A BR112012018954A2 BR 112012018954 A2 BR112012018954 A2 BR 112012018954A2 BR 112012018954 A BR112012018954 A BR 112012018954A BR 112012018954 A BR112012018954 A BR 112012018954A BR 112012018954 A2 BR112012018954 A2 BR 112012018954A2
- Authority
- BR
- Brazil
- Prior art keywords
- naphthyridine derivatives
- hetaryl
- naphthyridine
- derivatives
- heteryl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10001251 | 2010-02-05 | ||
| PCT/EP2010/007743 WO2011095196A1 (en) | 2010-02-05 | 2010-12-17 | Hetaryl-[1,8]naphthyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012018954A2 true BR112012018954A2 (pt) | 2016-04-12 |
Family
ID=43531801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018954A BR112012018954A2 (pt) | 2010-02-05 | 2010-12-17 | derivados de hetaril-[1,8]naftiridina |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8614226B2 (enExample) |
| EP (1) | EP2531500B1 (enExample) |
| JP (1) | JP5675850B2 (enExample) |
| KR (1) | KR20120124469A (enExample) |
| CN (1) | CN102741249B (enExample) |
| AU (1) | AU2010344973B2 (enExample) |
| BR (1) | BR112012018954A2 (enExample) |
| CA (1) | CA2789021C (enExample) |
| EA (1) | EA201201081A1 (enExample) |
| ES (1) | ES2667049T3 (enExample) |
| MX (1) | MX2012008550A (enExample) |
| SG (1) | SG182803A1 (enExample) |
| WO (1) | WO2011095196A1 (enExample) |
| ZA (1) | ZA201206630B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011101069A2 (en) * | 2010-02-22 | 2011-08-25 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| UA112758C2 (uk) * | 2010-07-07 | 2016-10-25 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб введення молекули функціоналізованої лінійної нуклеотидної касети у клітину, що містить клітинну стінку |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| CA2887203A1 (en) | 2012-10-05 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | 2,3-(hetero)aryl substituted pyridinyl compounds and their use as gdf-8 inhibitors |
| MA38287B1 (fr) | 2013-01-23 | 2018-08-31 | Astrazeneca Ab | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer |
| CN103113369A (zh) * | 2013-03-21 | 2013-05-22 | 云南大学 | 一种具有抗肿瘤活性的苯并[b][1,8]-萘啶-2-(1H)-亚胺衍生物及合成方法 |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| AU2014354711B2 (en) | 2013-11-27 | 2018-10-25 | Signalchem Lifesciences Corporation | Aminopyridine derivatives as TAM family kinase inhibitors |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US10233170B2 (en) * | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
| IL277071B2 (en) | 2018-03-08 | 2024-07-01 | Incyte Corp | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR207555A1 (es) * | 1972-12-04 | 1976-10-15 | Procedimiento para preparar aril-6-piperazinocarboniloxi-5 oxo-7 tetrahidro-2,3,6,7 ditiino(1,4)(2,3-c)pirroles | |
| IT1245712B (it) * | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree |
| US5994367A (en) | 1997-03-07 | 1999-11-30 | The University Of North Carolina At Chapel Hill | Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| PL203140B1 (pl) | 1997-10-27 | 2009-08-31 | Neurosearch As | Pochodna homopiperazyny, kompozycja farmaceutyczna zawierająca te pochodne i zastosowanie tej pochodnej |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| GB0117060D0 (en) * | 2001-07-12 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003229305A1 (en) * | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| EP1603908B1 (en) | 2003-03-12 | 2008-06-11 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| EP1724268A4 (en) | 2004-02-20 | 2010-04-21 | Kirin Pharma Kk | COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| SI2607362T1 (sl) * | 2005-02-17 | 2015-03-31 | Astellas Pharma Inc. | Piperidinski in piperazinski karboksilati kot FAAH inhibitorji |
| RU2384331C2 (ru) | 2005-12-05 | 2010-03-20 | Пфайзер Продактс Инк. | Способ лечения аномального роста клеток |
| JP4751856B2 (ja) | 2007-07-03 | 2011-08-17 | 本田技研工業株式会社 | 車体側部構造 |
| DE102007049451A1 (de) | 2007-10-16 | 2009-04-23 | Merck Patent Gmbh | 5-Cyano-thienopyridine |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| DE102008017853A1 (de) | 2008-04-09 | 2009-10-15 | Merck Patent Gmbh | Thienopyrimidine |
| PT2307402E (pt) | 2008-04-29 | 2013-02-15 | Novartis Ag | Derivados de imidazo-piridina como inibidores de cinase semelhante ao recetor de ativina (alk4 ou alk5) |
| CA2765819A1 (en) * | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses as inhibitors of pi3 k activity |
| WO2011101069A2 (en) * | 2010-02-22 | 2011-08-25 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
-
2010
- 2010-12-17 AU AU2010344973A patent/AU2010344973B2/en not_active Ceased
- 2010-12-17 US US13/574,282 patent/US8614226B2/en active Active
- 2010-12-17 ES ES10794897.8T patent/ES2667049T3/es active Active
- 2010-12-17 WO PCT/EP2010/007743 patent/WO2011095196A1/en not_active Ceased
- 2010-12-17 BR BR112012018954A patent/BR112012018954A2/pt not_active IP Right Cessation
- 2010-12-17 EP EP10794897.8A patent/EP2531500B1/en not_active Not-in-force
- 2010-12-17 MX MX2012008550A patent/MX2012008550A/es not_active Application Discontinuation
- 2010-12-17 CA CA2789021A patent/CA2789021C/en not_active Expired - Fee Related
- 2010-12-17 EA EA201201081A patent/EA201201081A1/ru unknown
- 2010-12-17 CN CN201080063064.6A patent/CN102741249B/zh not_active Expired - Fee Related
- 2010-12-17 KR KR1020127022601A patent/KR20120124469A/ko not_active Withdrawn
- 2010-12-17 SG SG2012056495A patent/SG182803A1/en unknown
- 2010-12-17 JP JP2012551506A patent/JP5675850B2/ja not_active Expired - Fee Related
-
2012
- 2012-09-04 ZA ZA2012/06630A patent/ZA201206630B/en unknown
-
2013
- 2013-10-04 US US14/046,703 patent/US8912216B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201206630B (en) | 2013-05-29 |
| CN102741249A (zh) | 2012-10-17 |
| CA2789021C (en) | 2018-02-06 |
| JP2013518832A (ja) | 2013-05-23 |
| KR20120124469A (ko) | 2012-11-13 |
| WO2011095196A1 (en) | 2011-08-11 |
| JP5675850B2 (ja) | 2015-02-25 |
| US20120295902A1 (en) | 2012-11-22 |
| ES2667049T3 (es) | 2018-05-09 |
| MX2012008550A (es) | 2012-09-07 |
| CN102741249B (zh) | 2015-11-25 |
| US20140038960A1 (en) | 2014-02-06 |
| US8614226B2 (en) | 2013-12-24 |
| AU2010344973B2 (en) | 2016-06-16 |
| CA2789021A1 (en) | 2011-08-11 |
| AU2010344973A1 (en) | 2012-09-20 |
| EA201201081A1 (ru) | 2013-03-29 |
| EP2531500A1 (en) | 2012-12-12 |
| SG182803A1 (en) | 2012-09-27 |
| US8912216B2 (en) | 2014-12-16 |
| EP2531500B1 (en) | 2018-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018954A2 (pt) | derivados de hetaril-[1,8]naftiridina | |
| BR112012019561A2 (pt) | hetarilamino naftiridinas | |
| CY1124874T1 (el) | Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| MY156938A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| BR112013019028A2 (pt) | derivados de 7-azaindol | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| BRPI0908637B8 (pt) | composto e composição farmacêutica do mesmo | |
| GEP20166484B (en) | Protein kinase inhibitors | |
| MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
| JO3073B1 (ar) | مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3 | |
| EA201170832A1 (ru) | Пуриновые соединения | |
| EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| BR112013029640A2 (pt) | derivados de piridina e pirazina | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| GEP20156242B (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| CA2878796C (en) | Derivatives of pyridinone as inhibitors for tissue transglutaminase | |
| MX2012015100A (es) | Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina. | |
| EA201070009A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
| GEP20156346B (en) | Imidazole derivatives as pde10a enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |